In this paper,the Ni/Al_(2)O_(3) monolithic catalyst with 15%Ni content was prepared using cordierite as a matrix,and the catalyst was modified with 10%NaOH to study the methanation performance of biomass gasification...In this paper,the Ni/Al_(2)O_(3) monolithic catalyst with 15%Ni content was prepared using cordierite as a matrix,and the catalyst was modified with 10%NaOH to study the methanation performance of biomass gasification simulated gas based on alkali-modified Ni/Al_(2)O_(3) monolithic catalyst.BET,TEM,H_(2)-TPR,XRD,CO_(2)-TPD and TG were used to characterize the physicochemical properties of the catalyst before and after modification.The results indicated that the CO conversion rate trends of unmodified and modified Ni/Al_(2)O_(3) monolithic catalysts over 2 h were fundamentally consistent.However,the Ni/Al_(2)O_(3) catalysts modified for 2 h demonstrated significantly enhanced performance compared to those modified for 1 h.Regarding CH4 selectivity,the modified Ni/Al_(2)O_(3) catalyst exhibited markedly better performance than the unmodified Ni/Al_(2)O_(3) catalyst,confirming the enhanced methane performance of the alkali-modified Ni/Al_(2)O_(3) monolithic catalyst.Under optimized conditions(H_(2)/CO volume ratio of 3∶1,space velocity of 10000 mL/(g·h),and temperature of 400℃),the methanation performance of the Ni/Al_(2)O_(3) monolithic catalyst modified for 2 h reached its peak,achieving a CO conversion rate of 97%with 100%CH4 selectivity.展开更多
目的运用网络药理学分析方法进行仙灵骨葆治疗骨质疏松症(osteoporosis,OP)的药理机制分析。方法借助中药系统药理学数据库和分析平台以及中药综合数据库获取仙灵骨葆活性成分以及相关靶标,运用Cytoscape 3.7.1软件绘制“活性成分-靶标...目的运用网络药理学分析方法进行仙灵骨葆治疗骨质疏松症(osteoporosis,OP)的药理机制分析。方法借助中药系统药理学数据库和分析平台以及中药综合数据库获取仙灵骨葆活性成分以及相关靶标,运用Cytoscape 3.7.1软件绘制“活性成分-靶标”网络图,以“osteoporosis”为关键词从GeneCards:The Human Gene Database获取OP相关基因,运用STRING数据分析平台进行PPI(protein-protein interaction)网络分析,运用DAVID数据分析平台进行基因本体(gene ontology,GO)生物过程富集以及京都基因与基因组百科全书(Kyoto Encyclopedia of Genes and Genomes,KEGG)通路富集分析,并运用Cytoscape 3.7.1软件绘制“通路-靶标”网络图。结果共获取仙灵骨葆相关活性成分115种,核心活性成分有槲皮素、山奈酚、木犀草素、淫羊藿苷元、丹参酮IIA等。活性成分所涉及的靶标共有301个,核心靶标有PTGS2、PTGS1、ESR1等。PPI网络显示了111种核心蛋白之间的互作关系,主要与调节细胞周期有关。GO富集生物过程经筛选后共获得46项,所得生物过程亦与细胞周期有关,正调控NF-kappaB转录活性因子的过程是OP发生的机制之一,与现有研究符合。KEGG通路富集共获得37项,提示仙灵骨葆治疗OP作用集中于PI3K-Akt、TNF、MAPK、Estrogen等信号通路。结论仙灵骨葆核心活性成分中,黄酮类化合物主要通过调节OPG/RANK/RANKL,抑制破骨细胞,促进成骨细胞分化;淫羊藿苷元可增强成骨细胞活性。核心靶标PTGS2可限制M-CSF以及RANKL的表达,进而影响成骨/破骨细胞分化;雌激素受体与绝经后骨质疏松密切相关。核心通路如PI3K-Akt信号通路可增加骨量、促进成骨细胞分化;TNF信号通路、MAPK信号通路等均与成骨细胞分化有关;雌激素信号通路以及GnRh信号通路为仙灵骨葆干预绝经后骨质疏松提供依据。因此仙灵骨葆干预OP机制是通过多种途径、多种靶标、多种信号通路同时进行的,运用网络药理学方法可以在一定程度上对其进行预测。展开更多
基金Supported by the National Natural Science Foundation of China(52506188,52476215)Natural Science Foundation of Liaoning Province(2024-MS-139,2024JH3/10200047)Scientific Research Program of Department of Education of Liaoning Province(310125042,LJ212410143033。
文摘In this paper,the Ni/Al_(2)O_(3) monolithic catalyst with 15%Ni content was prepared using cordierite as a matrix,and the catalyst was modified with 10%NaOH to study the methanation performance of biomass gasification simulated gas based on alkali-modified Ni/Al_(2)O_(3) monolithic catalyst.BET,TEM,H_(2)-TPR,XRD,CO_(2)-TPD and TG were used to characterize the physicochemical properties of the catalyst before and after modification.The results indicated that the CO conversion rate trends of unmodified and modified Ni/Al_(2)O_(3) monolithic catalysts over 2 h were fundamentally consistent.However,the Ni/Al_(2)O_(3) catalysts modified for 2 h demonstrated significantly enhanced performance compared to those modified for 1 h.Regarding CH4 selectivity,the modified Ni/Al_(2)O_(3) catalyst exhibited markedly better performance than the unmodified Ni/Al_(2)O_(3) catalyst,confirming the enhanced methane performance of the alkali-modified Ni/Al_(2)O_(3) monolithic catalyst.Under optimized conditions(H_(2)/CO volume ratio of 3∶1,space velocity of 10000 mL/(g·h),and temperature of 400℃),the methanation performance of the Ni/Al_(2)O_(3) monolithic catalyst modified for 2 h reached its peak,achieving a CO conversion rate of 97%with 100%CH4 selectivity.
文摘目的运用网络药理学分析方法进行仙灵骨葆治疗骨质疏松症(osteoporosis,OP)的药理机制分析。方法借助中药系统药理学数据库和分析平台以及中药综合数据库获取仙灵骨葆活性成分以及相关靶标,运用Cytoscape 3.7.1软件绘制“活性成分-靶标”网络图,以“osteoporosis”为关键词从GeneCards:The Human Gene Database获取OP相关基因,运用STRING数据分析平台进行PPI(protein-protein interaction)网络分析,运用DAVID数据分析平台进行基因本体(gene ontology,GO)生物过程富集以及京都基因与基因组百科全书(Kyoto Encyclopedia of Genes and Genomes,KEGG)通路富集分析,并运用Cytoscape 3.7.1软件绘制“通路-靶标”网络图。结果共获取仙灵骨葆相关活性成分115种,核心活性成分有槲皮素、山奈酚、木犀草素、淫羊藿苷元、丹参酮IIA等。活性成分所涉及的靶标共有301个,核心靶标有PTGS2、PTGS1、ESR1等。PPI网络显示了111种核心蛋白之间的互作关系,主要与调节细胞周期有关。GO富集生物过程经筛选后共获得46项,所得生物过程亦与细胞周期有关,正调控NF-kappaB转录活性因子的过程是OP发生的机制之一,与现有研究符合。KEGG通路富集共获得37项,提示仙灵骨葆治疗OP作用集中于PI3K-Akt、TNF、MAPK、Estrogen等信号通路。结论仙灵骨葆核心活性成分中,黄酮类化合物主要通过调节OPG/RANK/RANKL,抑制破骨细胞,促进成骨细胞分化;淫羊藿苷元可增强成骨细胞活性。核心靶标PTGS2可限制M-CSF以及RANKL的表达,进而影响成骨/破骨细胞分化;雌激素受体与绝经后骨质疏松密切相关。核心通路如PI3K-Akt信号通路可增加骨量、促进成骨细胞分化;TNF信号通路、MAPK信号通路等均与成骨细胞分化有关;雌激素信号通路以及GnRh信号通路为仙灵骨葆干预绝经后骨质疏松提供依据。因此仙灵骨葆干预OP机制是通过多种途径、多种靶标、多种信号通路同时进行的,运用网络药理学方法可以在一定程度上对其进行预测。
